



MENARINI
group



COMPANY PROFILE

11st October 2024




Menarini was
founded in 1886.

In 1915 its
headquarters were
established
in **Florence.**

Milestones

Since 1992, the Menarini Group has reinvested all profits in its growth



Milestones



2011

ASIA PACIFIC

Menarini makes its entry into Asia Pacific thanks to the acquisition of a company based in **Singapore** and present in **13 countries** throughout the region, from China to Australia.

2013
2016

SILICON BIOSYSTEMS

Acquisition of Silicon Biosystems, a start-up of innovative technologies for liquid biopsies.

CELLSEARCH

Acquisition of Cell Search, an FDA approved technology in the field of **circulating tumor cells**.

2020

U.S.A.

Menarini makes its entrance into the USA through to the acquisition of **Stemline Therapeutics**, biopharmaceutical company publicly listed on NASDAQ, and their product **Tagraxofusp**, the only FDA approved therapy available for BPDCN, thus strengthening Menarini's presence in oncology.


2023

FDA&EMA

U.S. FDA and EU (EMA) approve **Elacestrant** as the first treatment for patients with ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer.

Consolidated turnover


Million euro




Source: internal data.

Consolidated turnover

Pharmaceutical **96%**



International **79%**




Source: internal data.

Menarini in the **WORLD**

Present in **140 countries** worldwide (with its affiliates, distributors and franchises).




Number of employees



Source: internal data.

Employees % of graduates and technicians



18 manufacturing plants

EUROPE is the Group's heart of production

In 2023 **609 million packs** were produced at these sites

Italy

Pisa (2 plants), Florence (2 plants)
Pomezia*, L'Aquila, Lomagna (Lecco),
Casaletto Lodigiano (Lodi)

Spain

Barcelona

Germany

Berlin (2 plants), Dresden

Plants dedicated to the **production for local markets** are located in Central America (Guatemala City), Ireland (Shannon), Turkey (Istanbul), Russia (Kaluga) and Indonesia (Jakarta).

U.S.A. (Philadelphia - Huntingdon Valley): **diagnostic production**



*Biotech manufacturing with development and production processes also for third parties.

9 Research & Development centers



*Pomezia.

Research & Development Projects **ONCOLOGY**

SOLID TUMORS

COMPOUND	DRUG CLASS (TARGET)	INDICATION	DEVELOPMENT STAGE
Elacestrant^o	SME (SERD - ER)	Monotherapy: ER+/HER2- Metastatic Breast Cancer (<i>EMERALD</i> trial)	EMA and FDA: approved
Elacestrant	SME (SERD - ER)	Monotherapy: CDK4/6 Inhibitor-naïve ER+/HER2- Metastatic Breast Cancer (<i>ELGIN</i> trial)	Phase II
Elacestrant	SME (SERD - ER)	Combination therapy: ER+/HER2- Metastatic Breast Cancer (<i>ELEVATE</i> trial)	Phase II
Elacestrant	SME (SERD - ER)	Combination therapy: ER+/HER2- Breast Cancer with brain metastasis (<i>ELECTRA</i> trial)	Phase II
Elacestrant	SME (SERD - ER)	Combination therapy: ER+/HER2- Metastatic or locally Advanced Breast Cancer (<i>SUMIT-ELA</i> trial)*	Phase II
Elacestrant	SME (SERD - ER)	Combination therapy: ER+/HER2- , ESR-1 mut, Advanced Breast Cancer (<i>ADELA</i> trial)**	Phase III
SL-701	IT (IL-13R α 2, EphA2, Survivin)	Recurrent Glioblastoma	Phase II
MEN1611	SME (PI3Ki)	Colorectal Cancer	Phase II
MEN1611	SME (PI3Ki)	Breast Cancer	Phase II
MEN1309	ADC (Anti-CD205)	Solid Tumors	Phase Ib
Felezonexor	SME (XP01i)	Solid Tumors	Phase Ib
MEN2312	SME (KAT6i)	Breast Cancer/Solid tumors and HEME malignancies	Phase I
Selinexor	SME (XP01i)	Endometrial Cancer***	Phase III

HEMATOLOGY

COMPOUND	DRUG CLASS (TARGET)	INDICATION	DEVELOPMENT STAGE
Tagraxofusp	TB (CD123)	Monotherapy: Blastic plasmacytoid dendritic cell neoplasm (BPDCN)	EMA and FDA: approved
Tagraxofusp	TB (CD123)	Monotherapy: Chronic myelomonocytic leukemia (CMML)	Phase II
Tagraxofusp	TB (CD123)	Monotherapy: Myelofibrosis (MF)	Phase II
Tagraxofusp	TB (CD123)	Combination therapy: Acute Myeloid Leukemia (AML)	Phase II
MEN1703	SME (PIM/FLT3i)	Combination therapy: Relapsed/refractory Diffuse Large B-cell Lymphoma (DLBCL)	Phase II
Selinexor^{oo}	SME (XP01i)	Combination therapy: Relapsed/refractory Multiple Myeloma	EMA and FDA: approved
Selinexor	SME (XP01i)	Combination therapy: Myelofibrosis***	Phase III

^o <https://www.menarini.com/en-us/news/news-detail/european-commission-approves-menarini-groups-orserdu174-elacestrant-for-the-treatment-of-patients-with-er-her2-locally-advanced-or-metastatic-breast-cancer-with-an-activating-esr1-mutation>
^{*} In collaboration with Carrick Therapeutics

^{**} In co-sponsorship with MedSir

^{***} Karyopharm trial. Based on the Licensing agreement in force, Menarini has Exclusive Rights to Commercialize NEXPOVIO for the Treatment of Hematologic and Solid Tumor Oncology Indications in Europe (including the United Kingdom), Latin America and Other Key Countries

^{oo} <https://www.menarini.com/it-it/news/dettaglio-news/karyopharm-and-menarini-group-receive-full-marketing-authorisation-from-the-european-commission-for-nexpiov174-selinexor-for-the-treatment-of-patients-with-multiple-myeloma-after-at-least-one-prior-t>

SERD, Selective Estrogen Receptor Degradable; IT, Immunotherapy;
SME, Small Molecule Entity; ADC, Antibody Drug Conjugate;
TB, Targeted Biologic; SME, Small Molecule Entity

Research & Development Projects **CARDIO-METABOLIC**

COMPOUND	DRUG CLASS	INDICATION	DEVELOPMENT STAGE
Obicetrapib	Cholesteryl ester transfer protein (CETP) inhibitor	Lipid Lowering agent administered to patients previously treated with statins Prevention of Major Adverse CardioVascular events	Phase III
Obicetrapib+Ezetimibe	Cholesteryl ester transfer protein (CETP) inhibitor + Niemann-Pick C1-like 1 (NPC1L1) protein inhibitor	Lipid Lowering agent administered to patients previously treated with statins	Phase III

<https://www.menarini.com/en-us/news/news-detail/newamsterdam-pharma-and-the-menarini-group-sign-licensing-deal-to-commercialize-obicetrapib-in-europe>

Research & Development Projects **ANTI-INFECTIVES**

COMPOUND	DRUG CLASS	INDICATION	DEVELOPMENT STAGE
Meropenem + Vaborbactam	Carbapenem + β -lactamase inhibitor	Complicated urinary tract infections, Complicated Intra abdominal infections, Hospital acquired pneumonia, Ventilator associated pneumonia and Bacteremia	EMA, FDA, Hong Kong, Thailand and Macao: approved
Delafloxacin	Anionic fluoroquinolone	Acute Bacterial Skin and Skin Structure – ABSSSI Community Acquired Bacterial Pneumonia - CABP	EMA and FDA: approved
Oritavancin	Semisynthetic glycopeptide	Acute Bacterial Skin and Skin Structure - ABSSSI	EMA and FDA: approved
Oritavancin (new formulation)	Semisynthetic glycopeptide	Acute Bacterial Skin and Skin Structure - ABSSSI	EMA and FDA: approved
Cefepime + Taniborbactam	beta-lactam + β -lactamase inhibitor	Complicated urinary tract and intra abdominal infections, Hospital-acquired bacterial pneumonia and Ventilator-associated bacterial pneumonia	Phase III

Menarini For People: our social responsibility projects



Wheelchair basketball

Volpi Rosse Menarini in Italy and Menarini Joventut in Spain
When sport can help break down barriers and foster inclusion and independence



A pediatricians' network

Educate up 15.000 "sentinel doctors" recognise child abuse



Together with Red Cross

Contributions to support populations in emergency



Menarini Forest

15.000 trees planted in several countries all over the world



Standing by children in difficulty

Healthcare, nutrition and education for children from economically disadvantaged families



Donations of medicines

To support those in need and promote better health for all

Menarini Foundation

**FONDAZIONE
MENARINI**

The “Fondazione Menarini” was founded in the spring of 1976 to promote research and knowledge in the fields of biology, pharmacology and medicine, but also in the fields of economy and human sciences.

EVENTS

More than 600 International Events,
2.000 Speakers and 75.000 attendees.
Live streaming in 3 languages.



«Think Tank» which, since 2022, promotes initiatives for change on social, economic and cultural issues in Italy.

HOUSE OF SCIENCES


More than 3.000 articles available free of charge and video interviews with 10 Nobel laureates.

- **Scientific Library** – 8 therapeutic areas
- **Dialogs Beyond Borders** – video interviews

MINUTI

- **Minuti Science** - Website dedicated to Minuti Science edition.
- **Minuti Art** - Website dedicated to Minuti Art edition.





FAIR PLAY MENARINI INTERNATIONAL AWARD



Ethics, Loyalty, Respect



Now in its 28th edition, the Fair Play Menarini International Award promotes the fundamental values of sport.

The award winners become Fair Play Ambassadors, symbolising outstanding sporting feats achieved in the name of fair play and respect.

Over 400 award winners, including: Stefan Edberg, Casey Stoner, Ian Thorpe, Edwin Moses, Tommie Smith, Luis Scola, Zico.



MENARINI
group

